Glucotrack

Glucotrack is an innovator in the diabetes care space, developing a long-term implantable continuous glucose monitor (CBGM) designed to break the typical 3-year longevity barrier of current devices. The company has completed its first human clinical study and is progressing toward commercialization, targeting a solution that is less disruptive for patients and generates less environmental waste. Led by a seasoned team with deep expertise from companies like DexCom and Medtronic, Glucotrack is positioning itself to challenge the established CGM market with a differentiated, fully implantable product. The technology remains investigational and has not yet received FDA approval.

Fully implantable long-term continuous blood glucose monitoring (CBGM) system designed to measure glucose directly from the blood, eliminating external wearables and targeting a functional lifespan beyond 3 years.

Glucotrack competes in the CGM market, which is dominated by DexCom (G6/G7), Abbott (FreeStyle Libre), and Medtronic. Its fully implantable, multi-year device is a distinct approach, contrasting with the dominant disposable subcutaneous sensor model. It also faces potential competition from other long-term implant developers, though the field is less crowded than the external CGM space.